CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cloud-based molecular Laboratory Information Management Software (LIMS) leader Ovation today announced the formal launch of the Ovation Research Network.
The Ovation Research Network is a platform of clinical laboratories who use Ovation’s LIMS solution and also contribute consented biospecimens for research purposes.
The Network is led by Ovation Co-founder and Chief Strategy Officer, Barry Wark. It currently consists of 21 independent, geographically and demographically diverse clinical labs across the U.S., with plans to double the number of labs by the end of 2022.
The Network provides a channel for labs to contribute to the discovery and development of novel precision therapies, while also providing an additional revenue stream to clinical labs who use Ovation’s leading LIMS solution.
Today, Ovation also announced the Network’s participation in the National Institutes of Health's Rapid Acceleration of Diagnostics (RADx®) Tech Variant Task Force (VTF) by providing real-world input to a new cost-effective platform which tracks COVID-19 variants. Ovation’s involvement broadens the platform’s geographic diversity and provides greater insight into the spread and local prevalence of new variants.
In a recent Journal of Clinical Microbiology publication, the VTF team highlighted that known variants can be identified within one to two days using genotyping, which can be conducted for a fraction of the cost of next-generation sequencing. A public dashboard – the ROSALIND Tracker for COVID-19 – summarizes the team’s ongoing SARS-CoV-2 surveillance data, including new BA.4 and BA.5 subvariant identification. Currently, this effort is used for research purposes only.
“Ovation’s participation expands the platform’s geographic reach to rural and underserved populations, increasing the program’s relevance for the broader U.S. population,” said Clair O’Donovan, Ph.D., a team leader with the RADx Tech VTF.
Ovation Research Network labs contributing to the platform look forward to what’s ahead. Lisa Justesen, COO of Soft Cell Labs, said: “We are excited for the opportunity to directly contribute to timely and important research through our participation in the Ovation Research Network. The RADx Tech program is one example of the research initiatives to which we hope to continue contributing in the coming years.”
Ovation’s suite of software and data products make it easier for clinical labs to bring innovative tests to the patients that need them, while connecting life science researchers with the insights required to discover life-changing therapies faster. For more information, visit ovation.io.